These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3531332)

  • 1. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
    Merluzzi VJ; Trail PA; Last-Barney K
    J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis.
    Rolstad B; Benestad HB
    Immunology; 1991 Sep; 74(1):86-93. PubMed ID: 1937576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution.
    Maghazachi AA; Goldfarb RH; Herberman RB
    J Immunol; 1988 Dec; 141(11):4039-46. PubMed ID: 2846699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
    Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
    J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice.
    Merluzzi VJ; Savage DM; Smith MD; Last-Barney K; Mertelsmann R; Moore MA; Welte K
    J Immunol; 1985 Sep; 135(3):1702-6. PubMed ID: 3894518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lymphokine-activated killer cells as mediators of veto and natural suppression.
    Azuma E; Kaplan J
    J Immunol; 1988 Oct; 141(8):2601-6. PubMed ID: 3171179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of macromolecular insoluble cold globulin (MICG) as a new marker shared by NK and ADCC cells, but not expressed by NC cells.
    Campos-Perera C; Murgita RA; Hauptman SP; Gronvik KO
    Immunology; 1986 Sep; 59(1):101-7. PubMed ID: 2428732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Separation of lymphokine-activated killer cell precursors and T-cells: differential growth characteristics and apparent lack of a T-cell suppressor of LAK-cell induction.
    Rinehart JJ; Geidenberger C; Aldrich W
    Mol Biother; 1989; 1(3):133-9. PubMed ID: 2532518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
    Long GS; Cramer DV; Harnaha JB; Hiserodt JC
    Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of natural killer cells from bone marrow precursors in vitro.
    Kalland T
    Immunology; 1986 Apr; 57(4):493-8. PubMed ID: 3485566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility-1 antigen-specific bone marrow rejection in vivo.
    Murphy WJ; Kumar V; Bennett M
    Eur J Immunol; 1990 Aug; 20(8):1729-34. PubMed ID: 2209686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.